OBJECTIVES: The Current Opioid Misuse Measure (COMM) is a self-report measure of risk for aberrant medication-related behavior among persons with chronic pain who are prescribed opioids for pain. It was developed to complement predictive screeners of opioid misuse potential and improve a clinician's ability to periodically assess a patient's risk for opioid misuse. The aim of this study was to cross-validate the COMM with a sample of chronic noncancer pain patients. METHODS: Two hundred and twenty-six participants prescribed opioids for pain were recruited from 5 pain management centers in the United States. Participants completed the 17-item COMM and a series of self-report measures. Patients were rated by their treating physician, had a urine toxicology screen, and were classified on the Aberrant Drug Behavior index. RESULTS: The reliability and predictive validity in this cross validation as measured by the area under the curve (AUC) were found to be highly significant (AUC=0.79) and not significantly different from the AUC obtained in the original validation study (AUC=0.81). Reliability (coefficient α) was 0.83, which is comparable to the 0.86 obtained in the original sample. DISCUSSION: Results of the cross validation suggest that the psychometric parameters of the COMM are not based solely on unique characteristics of the initial validation sample. The COMM seems to be a reliable and valid screening tool to help detect current aberrant drug-related behavior among chronic pain patients.
OBJECTIVES: The Current Opioid Misuse Measure (COMM) is a self-report measure of risk for aberrant medication-related behavior among persons with chronic pain who are prescribed opioids for pain. It was developed to complement predictive screeners of opioid misuse potential and improve a clinician's ability to periodically assess a patient's risk for opioid misuse. The aim of this study was to cross-validate the COMM with a sample of chronic noncancer painpatients. METHODS: Two hundred and twenty-six participants prescribed opioids for pain were recruited from 5 pain management centers in the United States. Participants completed the 17-item COMM and a series of self-report measures. Patients were rated by their treating physician, had a urine toxicology screen, and were classified on the Aberrant Drug Behavior index. RESULTS: The reliability and predictive validity in this cross validation as measured by the area under the curve (AUC) were found to be highly significant (AUC=0.79) and not significantly different from the AUC obtained in the original validation study (AUC=0.81). Reliability (coefficient α) was 0.83, which is comparable to the 0.86 obtained in the original sample. DISCUSSION: Results of the cross validation suggest that the psychometric parameters of the COMM are not based solely on unique characteristics of the initial validation sample. The COMM seems to be a reliable and valid screening tool to help detect current aberrant drug-related behavior among chronic painpatients.
Authors: Seddon R Savage; David E Joranson; Edward C Covington; Sidney H Schnoll; Howard A Heit; Aaron M Gilson Journal: J Pain Symptom Manage Date: 2003-07 Impact factor: 3.612
Authors: Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison Journal: J Pain Symptom Manage Date: 2004-09 Impact factor: 3.612
Authors: Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison Journal: J Pain Date: 2008-01-22 Impact factor: 5.820
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Andrew H Rogers; Michael F Orr; Justin M Shepherd; Jafar Bakhshaie; Joseph W Ditre; Julia D Buckner; Michael J Zvolensky Journal: J Behav Med Date: 2020-06-27
Authors: Kevin E Vowles; Katie Witkiewitz; Karen J Cusack; Wesley P Gilliam; Karen E Cardon; Sarah Bowen; Karlyn A Edwards; Mindy L McEntee; Robert W Bailey Journal: J Pain Date: 2019-11-21 Impact factor: 5.820
Authors: Iman Parhami; Mark Hyman; Aaron Siani; Stephanie Lin; Michael Collard; Johnny Garcia; Laurie Casaus; John Tsuang; Timothy W Fong Journal: Subst Use Misuse Date: 2011-11-08 Impact factor: 2.164
Authors: Stephen F Butler; Kevin L Zacharoff; Sadaf Charity; Ryan A Black; Emma Chung; Antje Barreveld; Molly S Clark; Robert N Jamison Journal: Pain Med Date: 2016-04-20 Impact factor: 3.750
Authors: Shannon M Smith; Florence Paillard; Andrew McKeown; Laurie B Burke; Robert R Edwards; Nathaniel P Katz; Elektra J Papadopoulos; Bob A Rappaport; Ashley Slagle; Eric C Strain; Ajay D Wasan; Dennis C Turk; Robert H Dworkin Journal: J Pain Date: 2015-02-04 Impact factor: 5.820
Authors: Tristan I Evans; Elliott J Liebling; Traci C Green; Scott E Hadland; Melissa A Clark; Brandon D L Marshall Journal: J Addict Med Date: 2017 Jul/Aug Impact factor: 3.702
Authors: Elise N Marino; Kristen D Rosen; Antonio Gutierrez; Maxim Eckmann; Somayaji Ramamurthy; Jennifer Sharpe Potter Journal: Addict Behav Date: 2013-02-04 Impact factor: 3.913